Telix Pharmaceuticals Limited (ASX: TLX) has announced an educational investor webinar exploring the evolution of PSMA targeted therapy and the Company’s differentiated, multi-product approach to treating prostate cancer. The event is scheduled for 30 Apr 2026 at 9:30 a.m. AEST.
Figure 1: Telix Pharmaceuticals facility [Courtesy: Telix Pharmaceuticals]
The webinar comes as Telix continues to build one of the most advanced radiopharmaceutical pipelines in the world. The announcement was released on 28 Apr 2026, covering the Company’s strategy across the prostate cancer disease continuum.
Telix Pharmaceuticals PSMA Therapy Webinar Set for 30 Apr 2026
Telix’s Group Chief Medical Officer, Dr. David N. Cade, will host the discussion. He will be joined by Professor Louise Emmett, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital in Sydney.
Professor Emmett will present data from her OPTIMAL-PSMA investigator-initiated trial of TLX597-Tx. This is Telix’s novel second-generation small molecule candidate being developed to broaden patient access to lutetium therapy in select geographies.
What the Webinar Will Cover
The session will explore what makes an effective PSMA targeted therapy. It is designed for investors seeking a deeper understanding of Telix Pharmaceuticals PSMA therapy and how its pipeline is positioned relative to the broader market.
The presentation will be followed by a live Q&A session. Participants can register for the webinar at the official conference link provided in the ASX announcement released on 28 Apr 2026.
Webinar Dates and Times
- AEST: Thursday 30 Apr 2026, 9:30 a.m.
- EDT: Wednesday 29 Apr 2026, 7:30 p.m.
What Is PSMA Targeted Therapy and How PSMA Treatment Works
PSMA stands for prostate-specific membrane antigen. It is a protein expressed at high levels on prostate cancer cells. This makes it an ideal target for both imaging and treatment using radiopharmaceuticals.
Figure 2: PSMA therapy mechanism illustration [Courtesy: MDPI Biomedicines]
How PSMA treatment works involves attaching a radioactive molecule to a targeting agent that binds to PSMA. Once administered, the therapy delivers radiation directly to the cancer cell. This precision approach minimises exposure to surrounding healthy tissue.
Telix’s Second-Generation Approach With TLX597-Tx
Telix Pharmaceuticals PSMA therapy strategy goes beyond existing approved treatments. TLX597-Tx uses a different targeting mechanism designed to improve biodistribution. Early clinical data from OPTIMAL-PSMA suggest limited uptake in healthy organs such as salivary glands and kidneys.
The Company is developing TLX597-Tx specifically for regions where access to approved lutetium PSMA therapies remains limited. This positions the candidate as an access-focused next-generation solution in the PSMA targeted therapy space.
Q1 2026 Update Reflects Momentum Behind the PSMA Therapy Strategy
Telix reported Q1 2026 unaudited group revenue of US$230 million, up 11% quarter-over-quarter. Precision Medicine revenue reached US$186 million for the quarter, up 16% quarter-over-quarter, driven by strong performance in both Illuccix and Gozellix segments.
The Company reaffirmed its FY 2026 revenue guidance of US$950 million to US$970 million. Research and development expenditure guidance was also reaffirmed at US$200 million to US$240 million for the full year.
TLX ASX Share Price
Telix Pharmaceuticals Limited (ASX: TLX) is currently trading at A$14.470 per share, with a market capitalisation of A$4.98B. The 52-week range stands at A$8.260 to A$29.640 per share.
Figure 3: TLX share price performance over the past year on the ASX [Courtesy: ASX]
Industry Outlook
The global radiopharmaceutical market is expanding rapidly, driven by growing clinical adoption of PSMA targeted therapy for prostate cancer. Lutetium-based treatments have emerged as a central pillar of precision oncology, attracting significant investment from biopharmaceutical companies worldwide.
Australia continues to position itself as a key hub for theranostics innovation, with clinical trial activity accelerating across major institutions.
Future Direction and Impact on TLX Investors
For investors following Telix Pharmaceuticals PSMA therapy developments, the 30 Apr 2026 webinar offers direct access to clinical data and strategic commentary. The OPTIMAL-PSMA trial data to be presented by Professor Emmett will provide early indicators of TLX597-Tx’s clinical profile.
The broader pipeline continues to mature, with ProstACT Global Part 1 meeting its safety objectives and Part 2 now open for enrolment across multiple countries.
How PSMA treatment works at a next-generation level is precisely what this webinar is designed to address for the investment community.
Frequently Asked Questions
Q1. What is the Telix Pharmaceuticals investor webinar about?
Ans. It is an educational session exploring PSMA targeted therapy and Telix’s multi-product approach to treating prostate cancer across the disease continuum.
Q2. When is the Telix webinar scheduled?
Ans. The webinar is set for 30 Apr 2026 at 9:30 a.m. AEST, or 29 Apr 2026 at 7:30 p.m. EDT.
Q3. What is TLX597-Tx?
Ans. TLX597-Tx is Telix’s second-generation PSMA targeted therapy candidate being developed to expand patient access to lutetium treatment in select geographies.
Q4. How does PSMA treatment work?
Ans. A radioactive molecule is attached to an agent that binds to PSMA on cancer cells, delivering targeted radiation directly to the tumour while limiting impact on healthy tissue.
Q5. Has TLX597-Tx received regulatory approval?
Ans. No. TLX597-Tx has not received a marketing authorisation in any jurisdiction as of the announcement date.
Disclaimer
This article is intended for informational purposes only and does not constitute financial or investment advice. All content is based on the ASX announcement released by Telix Pharmaceuticals Limited. Share price and market capitalisation data reflect figures provided at the time of publication. Investing in securities involves risk, including the possible loss of principal. Readers should conduct their own research and seek independent financial advice before making any investment decisions. Colitco does not hold any position in the companies or organisations mentioned.
Sources
https://www.asx.com.au/markets/company/TLX
Last modified: April 28, 2026
